Equities Analysts Offer Predictions for Harrow Q3 Earnings

Key Points

• William Blair raised Harrow's Q3 2025 earnings estimate from $0.08 to $0.13 per share and maintains an "Outperform" rating on the stock.
• Harrow stock has an average rating of "Buy" with a consensus price target of $64.67, supported by multiple analysts including HC Wainwright and Cantor Fitzgerald.
• The company recently reported $0.24 earnings per share, significantly exceeding analyst expectations, while also generating revenue of $63.74 million.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Stock analysts at William Blair increased their Q3 2025 earnings per share estimates for shares of Harrow in a report released on Tuesday, August 12th. William Blair analyst L. Hanbury-Brown now anticipates that the company will earn $0.13 per share for the quarter, up from their previous forecast of $0.08. William Blair has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share. William Blair also issued estimates for Harrow's Q4 2025 earnings at $0.07 EPS, FY2025 earnings at $0.22 EPS and FY2026 earnings at $1.37 EPS.

Several other equities analysts also recently commented on HROW. Zacks Research upgraded Harrow from a "hold" rating to a "strong-buy" rating in a research report on Thursday, August 14th. BTIG Research lifted their target price on Harrow from $62.00 to $63.00 and gave the company a "buy" rating in a research note on Thursday, August 14th. Cantor Fitzgerald began coverage on Harrow in a research note on Friday, July 11th. They set an "overweight" rating and a $76.00 price objective for the company. Finally, HC Wainwright lifted their price objective on Harrow from $60.00 to $64.00 and gave the stock a "buy" rating in a research note on Wednesday, August 13th. One analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $64.67.

Harrow Stock Performance

Shares of HROW stock traded down $0.2220 during mid-day trading on Friday, reaching $38.0080. The stock had a trading volume of 296,469 shares, compared to its average volume of 482,431. The firm's 50 day simple moving average is $33.48 and its 200 day simple moving average is $28.98. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. Harrow has a one year low of $20.85 and a one year high of $59.23. The firm has a market cap of $1.41 billion, a PE ratio of -151.37 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Monday, August 11th. The company reported $0.24 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.23. The firm had revenue of $63.74 million during the quarter, compared to analyst estimates of $64.23 million. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%. Harrow has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On Harrow

Institutional investors and hedge funds have recently made changes to their positions in the company. Braidwell LP grew its position in Harrow by 106.3% during the fourth quarter. Braidwell LP now owns 907,039 shares of the company's stock worth $30,431,000 after buying an additional 467,401 shares in the last quarter. Voya Investment Management LLC boosted its stake in Harrow by 4,035.5% in the first quarter. Voya Investment Management LLC now owns 381,461 shares of the company's stock valued at $10,147,000 after buying an additional 372,237 shares in the last quarter. Diametric Capital LP acquired a new stake in Harrow in the second quarter valued at about $4,748,000. Bank of America Corp DE boosted its stake in Harrow by 266.8% in the second quarter. Bank of America Corp DE now owns 213,448 shares of the company's stock valued at $6,519,000 after buying an additional 155,258 shares in the last quarter. Finally, Divisadero Street Capital Management LP acquired a new stake in Harrow in the second quarter valued at about $4,293,000. Institutional investors and hedge funds own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.